natgillin/translations-raw huggingface dataset:
The additional study showed that agomelatine was more effective than sertraline, with a difference in HAM D scores of 1.68 after six weeks.
Dodatna su ispitivanja dokazala da je agomelatin djelotvorniji od sertralina, s razlikom u rezultatima na skali HAM D od 1,68 nakon šest tjedana.
The additional study showed that the oral solution and the tablets were equally effective in preventing rejection.
Dodatno ispitivanje pokazalo je da su oralna otopina i tablete podjednako djelotvorne u sprječavanju odbijanja.
The adequate dosing may be achieved with the two available strengths of Kaletra tablets: 100/25 mg and 200/50 mg.*
Odgovarajuća doza se može postići s dvije dostupne jačine Kaletra tableta: 100/25 mg i 200/50 mg.
The adequate dosing may be achieved with the two available strengths of lopinavir/ritonavir tablets: 100/25 mg and 200/50 mg.*
Odgovarajuća doza može se postići s dvije dostupne jačine tableta lopinavira/ritonavira: 100/25 mg i 200/50 mg.
The adhesive barrier must be removed using a sterile blunt-edged instrument (e.g., tongue depressor).
Adhezivna barijera mora se ukloniti pomoću sterilnog tupog instrumenta (npr. špatula za pregled ždrijela).
The adhesive barrier must be removed using a sterile blunt-edged instrument (e.g., tongue depressor).
Adhezivna barijera mora se ukloniti pomoću sterilnog tupog instrumenta (npr. špatule za pregled ždrijela).
The adhesive side is covered with a removable, clear, unprinted, diagonally cut, release liner.
Ljepljiva strana pokrivena je uklonjivom, prozirnom, neoznačenom, dijagonalno prerezanom zaštitnom folijom.
The adjudicated major bleeding and CRNM bleeding at any anatomical site were generally lower in the apixaban group as compared to the enoxaparin/warfarin group.
Utvrđenih značajnih krvarenja i klinički značajnih ali ne velikih krvarenja na bilo kojem anatomskom mjestu bilo je općenito manje u skupini apiksabana u odnosu na skupinu enoksaparina/varfarina.
The adjusted DBP changes from baseline were -8.4 (1.5) mmHg, -4.5 (1.6) mmHg and -3.5 (2.1) mmHg respectively.
Prilagođene DBP promjene od početne vrijednosti iznosile su -8,4 (1,5) mm Hg, - 4,5 (1,6) mm Hg odnosno -3,5 (2,1) mm Hg.
The adjusted effectiveness represents the percent reduction in IPD in the Synflorix vaccinated group compared to the unvaccinated group, controlling for confounding factors.
Prilagođena učinkovitost predstavlja postotak smanjenja IPB-a u skupini koja je cijepljena cjepivom Synflorix u usporedbi s necijepljenom skupinom, kontrolira zbunjujuće čimbenike.
The adjusted hazard ratio (HR) for death in the Tarceva group relative to the placebo group was 0.73 (95% CI, 0.60 to 0.87) (p = 0.001).
Prilagođeni omjer rizika (HR) smrti u Tarceva skupini u odnosu na placebo skupinu bio je 0,73 (95% CI, 0,60 do 0,87) (p = 0,001).
The adjusted mean change in body weight from baseline at 52 weeks was -1.0 kg for Eperzan (N = 122) and +1.7 kg for insulin lispro (N = 141).
Prilagođena srednja promjena tjelesne težine nakon 52 tjedna u odnosu na početnu vrijednost iznosila je -1,0 kg za Eperzan (N = 122) i +1,7 kg za inzulin lispro (N = 141).
The adjusted mean dietary phenylalanine tolerance in the Kuvan plus phenylalanine -restricted group was 80.6 mg/kg/day and was statistically significantly greater (p<0.001) than the adjusted mean dietary phenylalanine tolerance in dietary phenylalanine therapy alone group (50.1 mg/kg/day).
Prilagođena srednja vrijednost tolerancije na fenilalanin u prehrani u skupini koja je primala Kuvan uz prehranu siromašnu fenilalaninom iznosila je 80,6 mg/kg na dan i bila je statistički značajno veća (p<0,001) od prilagođene srednje vrijednosti tolerancije na fenilalanin u prehrani u skupini čija je terapija bila samo prehrana siromašna fenilalaninom (50,1 mg/kg na dan).
The adjusted mean treatment difference of 37 mL between the groups was not statistically significant (p=0.162).
Prilagođena srednja vrijednost terapijskih razlika od 37 ml između skupina nije bila statistički značajna (p=0,162).
The adjusted treatment difference (isavuconazole−voriconazole) was −2.7% (95 % confidence interval: −12.9; 7.5).
PrilagoĎena terapijska razlika (izavukonazol-vorikonazol) bila je -2,7% (95% interval pouzdanosti: −12,9; 7,5).
The adjusted treatment difference (voriconazole−isavuconazole) was 4.0 (95% confidence interval: −7.9; 15.9).
PrilagoĎena terapijska razlika (vorikonazol−izavukonazol) bila je 4,0 (95% interval pouzdanosti: −7,9; 15,9).
The adjustment is made after three to four weeks in long-term stable angina and after two weeks in long-term heart failure.
Prilagodba se provodi nakon tri do četiri tjedna u slučaju koronarne arterijske bolesti i nakon dva tjedna kod dugoročno stabilne angine.
The adjuvant includes also polysorbate 80 and sorbitan trioleate in a citrate buffer.
Adjuvans također uključuje polisorbat 80 i sorbitan-trioleat u citratnom puferu.
The administered dose corresponds to 500,000 to 1,000,000 autologous cells/cm2 of implantation matrix.
Primijenjena doza odgovara količini od 500 000 do 1 000 000 autolognih stanica/cm2 matriksa za implantaciju.
The administration materials must consist of non-DEHP, non-PVC tubing with appropriate filter.
Pribor za primjenu mora imati cijevi koje ne sadrže DEHP i PVC i imaju odgovarajući filtar.
The administration of 6–mercaptopurine with food may decrease systemic exposure slightly but this is unlikely to be of clinical significance.
Primjena 6-merkaptopurina s hranom može malo smanjiti sistemsku izloženost, ali nije vjerojatno da će to biti klinički značajno.
The administration of a PPI can be considered to prevent GI bleeding.
Može se razmotriti primjena PPI-a radi prevencije gastrointestinalnog krvarenja.
The administration of a single dose every 4 weeks for 2 to 4 months is efficacious against Demodex canis and leads to a marked improvement of clinical signs particularly in mild to moderate cases.
Primjena jedne doze svaka 4 tjedna, tijekom 2-4 mjeseca, učinkovita je u suzbijanju grinje Demodex canis te dovodi do znatnog poboljšanja kliničkih simptoma pogotovo kod blagih do umjerenih slučajeva demodikoze.
The administration of Clomicalm is not recommended in combination with, or within 2 weeks of therapy with, monoamine oxidase inhibitors.
Primjena Clomicalma ne preporučuje se u kombinaciji s inhibitorima monoamin oksidaza ili unutar dva tjedna od terapije inhibitorima monoamin oksidaza.
The administration of deoxycorticosterone with the product may lead to a moderate reduction of the natriuretic effects (reduction of urinary sodium excretion) of spironolactone.
Primjena deoksikortikosteroida s lijekom može uzrokovati umjereno smanjenje natriuretskih učinaka (redukcija lučenja natrija urinom) spironolaktona.
The administration of dexmedetomidine to puppies younger than 16 weeks and kittens younger than 12 weeks has not been studied.
Primjena deksmedetomidina na štencima mlađim od 16 tjedana i mačićima mlađima od 12 tjedana nije ispitivana.
The administration of dexmedetomidine to puppies younger than 16 weeks and kittens younger than 12 weeks has not been studied.
Primjena deksmedetomidina na štencima mlađima od 16 tjedana i mačićima mlađima od 12 tjedana nije ispitivana.
The administration of Efavirenz Teva with food may increase efavirenz exposure (see section 5.2) and may lead to an increase in the frequency of adverse reactions (see section 4.8).
Primjena Efavirenza Teva s hranom može povećati izloženost efavirenzu (vidjeti dio 5.2) i povećati učestalost nuspojava (vidjeti dio 4.8).
The administration of efavirenz with food may increase efavirenz exposure and may lead to an increase in the frequency of adverse reactions (see section 4.4).
Primjena efavirenza uz hranu može povećati izloženost efavirenzu i voditi ka povećanju učestalosti nuspojava (vidjeti dio 4.4).
The administration of eltrombopag tablet or powder for oral suspension with a high-calcium meal (e.g. a meal that included dairy products) significantly reduced plasma eltrombopag AUC0-∞ and Cmax.
Primjena eltrombopag tablete ili praška za oralnu suspenziju uz obrok s visokim udjelom kalcija (npr. obrok koji je uključivao mliječne proizvode) značajno je smanjio plazmatski AUC0-∞ i Cmax eltrombopaga.
The administration of factor IX can repress these inhibitors.
Primjena faktora IX može poništiti učinak ovih inhibitora.
The administration of general anaesthesia must be individualised based on the dog's response.
Primjena opće anestezije mora biti individualizirana na temelju odgovora pojedinog psa.
The administration of large intravenous doses (≥ 7 mg/kg) of Methylthioninium chloride Proveblue to individuals without methaemoglobinaemia induces nausea and vomiting, chest tightness, chest pain, tachycardia, apprehension, severe sweating, tremor, mydriasis, blue-green staining of the urine, blue staining of the skin and mucous membranes, abdominal pain, dizziness, paraesthesia, headache, confusion, hypertension, mild methaemoglobinaemia (up to 7%) and electrocardiogram changes (T wave flattening or inversion).
Primjena velikih intravenskih doza (≥ 7 mg/kg) lijeka Methylthioninium chloride Proveblue u osoba bez methemoglobinemije izaziva mučninu i povraćanje, stezanje u prsištu, bol u prsištu, tahikardiju, strah, jako znojenje, tremor, midrijazu, plavo-zelenu obojenost mokraće, plavo bojenje kože i sluznica, bol u abdomenu, omaglicu, paresteziju, glavobolju, konfuziju, hipertenziju, blagu methemoglobinemiju (do 7%) i promjene na elektrokardiogramu (ravnanje ili inverziju T vala).
The administration of levetiracetam to patients with renal impairment may require dose adjustment.
U bolesnika s oštećenjem bubrega može biti potrebno prilagođavanje doze levetiravetama.
The administration of levetiracetam to patients with renal impairment may require dose adjustment.
U bolesnika s oštećenjem bubrega može biti potrebno prilagođavanje doze Matevera.
The administration of medicinal products by the intrathecal (IT) route carries the risk of potentially serious infections, such as meningitis, which may be life threatening.
Primjena lijekova intratekalnim putem uključuje rizik od potencijalno ozbiljnih infekcija kao što je meningitis, koji može biti životno opasan.
The administration of Menveo one month after Tdap resulted in statistically significantly lower serogroup W135 seroresponses.
Primjena cjepiva Menveo mjesec dana nakon cjepiva Tdap rezultirala je statistički značajno nižim serološkim odgovorima na serogrupu W135.
The administration of Nimenrix one month after the DTaP-HBV-IPV/Hib vaccine resulted in lower rSBA GMTs against groups A, C and W-135 compared with co-administration (see section 4.5).
Primjena cjepiva Nimenrix jedan mjesec nakon cjepiva DTaP-HBV-IPV/Hib, rezultirala je nižim GMT rSBA za grupu A, C i W-135 u usporedbi s istovremenom primjenom (vidjeti dio 4.5).
The administration of radioactive medicinal products creates risks for other persons from external radiation or contamination from spills of urine, vomiting, etc.
Primjena radiofarmaceutika stvara rizik za druge osobe od vanjskog zračenja ili kontaminacije od prolivenog urina, povraćanja, itd.
The administration of radioactive medicinal products creates risks for other persons from external radiation or contamination from spills of urine, vomiting, etc.
Primjenom radioaktivnog lijeka nastaje rizik za druge ljude od vanjskog zračenja ili kontaminacije prolijevanjem urina, povraćanjem itd.
The administration of radiopharmaceuticals creates risks for other persons (including pregnant healthcare professionals) from external radiation or contamination from spill of urine, vomiting etc.
Primjena radiofarmaka rizična je za druge osobe (uključujući trudne zdravstvene djelatnice) jer može doći do vanjskog zračenja ili kontaminacije uslijed prolijevanja mokraće, povraćanja itd.
The administration of Rotarix should be postponed in subjects suffering from diarrhoea or vomiting.
Primjena cjepiva Rotarix mora se odgoditi u osoba koje imaju proljev ili povraćaju.
The administration of sevoflurane must be individualised based on the dog's response.
Primjena sevoflurana mora biti individualizirana na temelju odgovora pojedinog psa.
The administration of sunitinib should be interrupted and/or the dose reduced in patients without clinical evidence of CHF but with an ejection fraction <50% and >20% below baseline.
Primjenu sunitiniba treba privremeno prekinuti i/ili smanjiti dozu u bolesnika u kojih nema kliničkih dokaza kongestivnog zatajivanja srca, ali im je istisna frakcija < 50% i > 20% manja od početne vrijednosti.
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole i eradikacije bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živim životinjama ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
bi primjena VMP na životinjama ometala provođenje nacionalnog programa za dijagnostiku, nadzor i iskorjenjivanje bolesti ili da bi prouzročila poteškoće u potvrđivanju odsutnosti zaraze u živih životinja ili prehrambenih i drugih proizvoda dobivenih od tretiranih životinja.
The administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
Će primjena veterinarsko-medicinskog proizvoda na životinjama interferirati s provedbom nacionalnih programa za otkrivanje, kontrolu i iskorjenjivanje bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živih životinja ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnih programa za otkrivanje, kontrolu ili iskorjenjivanje bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živih životinja ili hrani ili drugim proizvodima dobivenim od tretiranih životinja
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnih programa za otkrivanje, kontrolu ili iskorjenjivanje bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živih životinja ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole i eradikacije bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živim životinjama ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole ili eradikacije bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živim životinjama ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena veterinarsko-medicinskog proizvoda na životinjama interferirati s provedbom nacionalnih programa za otkrivanje, kontrolu i iskorjenjivanje bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živih životinja ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
The administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena veterinarsko-medicinskog proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole i eradikacije bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živim životinjama ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena veterinarsko-medicinskog proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole ili iskorjenjivanja bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živim životinjama ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals. the disease to which the product is intended to confer immunity is largely absent from the territory in question.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole ili eradikacije bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živim životinjama ili hrani ili drugim proizvodima dobivenim od tretiranih životinja. je bolest za koju je odnosni proizvod namijenjen da pruži imunost, odsutna s odnosnog područja.
the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals. the disease to which the product is intended to confer immunity is largely absent from the territory in question.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole ili iskorjenjivanje bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živih životinja ili hrani ili drugim proizvodima dobivenim od tretiranih životinja. je bolest za koju je proizvod namijenjen da pruži imunost, u velikoj mjeri odsutna s odnosnog područja.
the administration of the product to animals will interfere with the implementation of a national programmes for the diagnosis, control and/or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnih programa za otkrivanje, kontrolu ili iskorjenjivanje bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živih životinja ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnih programa za otkrivanje, kontrolu ili iskorjenjivanje bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živih životinja ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnog programa za otkrivanje, kontrolu ili iskorjenjivanje bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živih životinja ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole i eradikacije bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živim životinjama ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.
the administration of the product to animals will interfere with the implementation of national programmes for the diagnosis, control and eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals. the disease to which the veterinary medicinal product is intended to confer immunity is largely absent from the territory.
će primjena proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole i eradikacije bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živim životinjama ili hrani ili drugim proizvodima dobivenim od tretiranih životinja. je bolest za koju je odnosni veterinarsko-medicinski proizvod namijenjen da pruži imunost, odsutna s tog područja.
the administration of the product to animals will interfere with the implementation of national programmes for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
će primjena veterinarsko-medicinskog proizvoda na životinjama interferirati s provedbom nacionalnog programa otkrivanja, kontrole ili eradikacije bolesti životinja ili će prouzročiti poteškoće u certificiranju odsutnosti zaraze u živim životinjama ili hrani ili drugim proizvodima dobivenim od tretiranih životinja.